Dengue hemorrhagic fever with special emphasis on immunopathogenesis
- PMID: 17645944
- DOI: 10.1016/j.cimid.2007.05.010
Dengue hemorrhagic fever with special emphasis on immunopathogenesis
Abstract
Dengue virus infections are a serious cause of morbidity and mortality in most tropical and subtropical areas of the world; Southeast and South Asia, Central and South America, and the Caribbean. Dengue virus infection can be asymptomatic or causes two forms of illness, dengue fever (DF) and dengue hemorrhagic fever (DHF), which is the severe form of dengue illness and often fatal. Pathogenesis of DHF has been analyzed, and two mechanisms are considered to be responsible. These include dengue serotype cross-reactive immune responses and virulence of the virus. The immunopathological mechanisms include a complex series of immune responses. Rapid increase in the levels of cytokines, especially TNF-alpha, and chemical mediators play a key role in inducing unique clinical manifestations of DHF such as plasma leakage, shock, and hemorrhagic manifestations. It is understood that the process is initiated by infection with a virulent dengue virus, often in the presence of antibodies that enhance dengue virus infection in secondary infection, and then triggered by rapidly elevated cytokines and chemical mediators that were produced by intense immune activation. However, complete understanding of the entire pathological mechanism is far from complete, and further studies are still needed.
Similar articles
-
Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection.Exp Biol Med (Maywood). 2008 Apr;233(4):401-8. doi: 10.3181/0707-MR-198. Exp Biol Med (Maywood). 2008. PMID: 18367628 Review.
-
Immunopathological mechanisms in dengue and dengue hemorrhagic fever.Curr Opin Infect Dis. 2006 Oct;19(5):429-36. doi: 10.1097/01.qco.0000244047.31135.fa. Curr Opin Infect Dis. 2006. PMID: 16940865 Review.
-
Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large.Rev Med Virol. 2001 Sep-Oct;11(5):301-11. doi: 10.1002/rmv.324. Rev Med Virol. 2001. PMID: 11590668 Review.
-
Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.FEBS J. 2007 Jun;274(12):2986-3002. doi: 10.1111/j.1742-4658.2007.05831.x. Epub 2007 May 17. FEBS J. 2007. PMID: 17509079
-
Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response.J Infect Dis. 2008 Mar 15;197(6):817-24. doi: 10.1086/528805. J Infect Dis. 2008. PMID: 18269315
Cited by
-
Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.Hum Vaccin Immunother. 2012 Sep;8(9):1259-71. doi: 10.4161/hv.21224. Epub 2012 Aug 16. Hum Vaccin Immunother. 2012. PMID: 22894958 Free PMC article. Clinical Trial.
-
Dengue shock.J Emerg Trauma Shock. 2011 Jan;4(1):120-7. doi: 10.4103/0974-2700.76835. J Emerg Trauma Shock. 2011. PMID: 21633580 Free PMC article.
-
Transcytosis Involvement in Transport System and Endothelial Permeability of Vascular Leakage during Dengue Virus Infection.Viruses. 2018 Feb 8;10(2):69. doi: 10.3390/v10020069. Viruses. 2018. PMID: 29419739 Free PMC article. Review.
-
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131. Hum Vaccin Immunother. 2014. PMID: 25483647 Free PMC article. Clinical Trial.
-
Differential induction of cytokines by human neonatal, adult, and elderly monocyte/macrophages infected with dengue virus.Viral Immunol. 2014 May;27(4):151-9. doi: 10.1089/vim.2013.0123. Epub 2014 May 6. Viral Immunol. 2014. PMID: 24801946 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
